在癌症中治疗树木的概率学
Tsung-Hung Yao1, Zhenke Wu1, Karthik Bharath2
1Department of Biostatistics, University of Michigan at Ann Arbor.
The annals of applied statistics
|September 15, 2023
概括
这项研究引入了一个新的贝叶斯框架来分析患者衍生异种移植 (PDX) 数据,确定协同作用的癌症治疗组合及其机制. 该方法通过估计治疗方法之间的机制相似性来揭示潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 计算生物学 计算生物学
- 生物统计学 生物统计学
背景情况:
- 确定协同作用的癌症治疗及其机制对于有效治疗至关重要.
- 患者衍生异种移植 (PDX) 提供了一个有价值的临床前模型,用于评估人类瘤样本上的多种治疗组合.
- 现有的方法缺乏强大的框架来分析PDX数据中的复杂关系.
研究的目的:
- 提出一个基于贝叶斯概率树的新框架 (Rx-tree) 来分析PDX数据.
- 为了推断层次的治疗关系,并量化治疗之间的机制相似性.
- 为了确定癌症治疗的潜在协同治疗组合.
主要方法:
- 开发了一个基于贝叶斯概率树的框架 (Rx-tree) 使用迪里克莱特扩散树.
- 通过使用两阶段算法推导出计算效率高的后置推理的封闭形式边际概率.
- 引入了治疗方法之间的机制相似性的新指标,考虑到估计不确定性.
主要成果:
- 拟议的Rx-tree框架准确地恢复了模拟研究中的治疗结构和相似性.
- 对PDX数据集的分析显示,在五种癌症类型中,估计的治疗相似性和已知的生物机制之间存在很高的一致性.
- 确定了新的,具有协同作用路径调节的潜在有效组合疗法.
结论:
- Rx-tree框架为分析PDX数据提供了一个强大的,计算效率高的方法.
- 这种方法有助于发现协同作用的治疗组合,并阐明它们的潜在生物机制.
- 这些发现为未来的癌症治疗临床研究提供了有希望的途径.
更多相关视频
相关概念视频
Survival Tree
105
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
Building a Survival Tree
Constructing a...
Building a Survival Tree
Constructing a...
105
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Hazard Ratio
154
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
154


